FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136351248> ?p ?o ?g. }

• W3136351248 endingPage "410" @default.
• W3136351248 startingPage "399" @default.
• W3136351248 abstract "STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to PD-(L)1 inhibition in KRASMUT and KRASWT LUAD is also unknown.Clinicopathologic and genomic data were collected from September 2013 to September 2020 from patients with advanced LUAD at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort. Clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts. The Cancer Genome Atlas transcriptomic data were interrogated to identify differences in tumor gene expression and tumor immune cell subsets, respectively, according to KRAS/STK11 and KRAS/KEAP1 comutation status.In the combined cohort (Dana-Farber Cancer Institute/Massachusetts General Hospital + Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center) of 1261 patients (median age = 61 y [range: 22-92], 708 women [56.1%], 1065 smokers [84.4%]), KRAS mutations were detected in 536 cases (42.5%), and deleterious STK11 and KEAP1 mutations were found in 20.6% (260 of 1261) and 19.2% (231 of 1202) of assessable cases, respectively. In each independent cohort and in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 hazard ratio [HR] = 2.04, p < 0.0001; KEAP1 HR = 2.05, p < 0.0001) and overall (STK11 HR = 2.09, p < 0.0001; KEAP1 HR = 2.24, p < 0.0001) survival to immunotherapy uniquely among KRASMUT but not KRASWT LUADs. Gene expression ontology and immune cell enrichment analyses revealed that the presence of STK11 or KEAP1 mutations results in distinct immunophenotypes in KRASMUT, but not in KRASWT, lung cancers.STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRASMUT but not among KRASWT LUAD. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration." @default.
• W3136351248 created "2021-03-29" @default.
• W3136351248 creator A5001355914 @default.
• W3136351248 creator A5005948108 @default.
• W3136351248 creator A5013639614 @default.
• W3136351248 creator A5013806712 @default.
• W3136351248 creator A5025095617 @default.
• W3136351248 creator A5025940494 @default.
• W3136351248 creator A5028895179 @default.
• W3136351248 creator A5029805571 @default.
• W3136351248 creator A5030072277 @default.
• W3136351248 creator A5030450694 @default.
• W3136351248 creator A5030622261 @default.
• W3136351248 creator A5034426537 @default.
• W3136351248 creator A5035581993 @default.
• W3136351248 creator A5037884911 @default.
• W3136351248 creator A5039160380 @default.
• W3136351248 creator A5042580225 @default.
• W3136351248 creator A5047053195 @default.
• W3136351248 creator A5048380048 @default.
• W3136351248 creator A5048517627 @default.
• W3136351248 creator A5052578824 @default.
• W3136351248 creator A5052689241 @default.
• W3136351248 creator A5060353514 @default.
• W3136351248 creator A5065133327 @default.
• W3136351248 creator A5069854182 @default.
• W3136351248 creator A5080682658 @default.
• W3136351248 creator A5081227348 @default.
• W3136351248 creator A5085217465 @default.
• W3136351248 creator A5085305921 @default.
• W3136351248 creator A5085529882 @default.
• W3136351248 creator A5086249998 @default.
• W3136351248 creator A5089180350 @default.
• W3136351248 creator A5089322688 @default.
• W3136351248 creator A5090956629 @default.
• W3136351248 date "2022-03-01" @default.
• W3136351248 modified "2023-10-10" @default.
• W3136351248 title "Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status" @default.
• W3136351248 cites W2002015567 @default.
• W3136351248 cites W2024728867 @default.
• W3136351248 cites W2044874695 @default.
• W3136351248 cites W2049553585 @default.
• W3136351248 cites W2145411470 @default.
• W3136351248 cites W2156353875 @default.
• W3136351248 cites W2273119405 @default.
• W3136351248 cites W2301707196 @default.
• W3136351248 cites W2346025119 @default.
• W3136351248 cites W2400514548 @default.
• W3136351248 cites W2527905628 @default.
• W3136351248 cites W2567564314 @default.
• W3136351248 cites W2605047615 @default.
• W3136351248 cites W2764232556 @default.
• W3136351248 cites W2767162493 @default.
• W3136351248 cites W2786224778 @default.
• W3136351248 cites W2792459030 @default.
• W3136351248 cites W2797675588 @default.
• W3136351248 cites W2803397860 @default.
• W3136351248 cites W2804812017 @default.
• W3136351248 cites W2883806089 @default.
• W3136351248 cites W2925446385 @default.
• W3136351248 cites W2943618951 @default.
• W3136351248 cites W2969539132 @default.
• W3136351248 cites W2982049472 @default.
• W3136351248 cites W2982321167 @default.
• W3136351248 cites W2993652631 @default.
• W3136351248 cites W2998945317 @default.
• W3136351248 cites W3012365695 @default.
• W3136351248 cites W3015304704 @default.
• W3136351248 cites W3017125932 @default.
• W3136351248 cites W3108354267 @default.
• W3136351248 cites W3120595252 @default.
• W3136351248 cites W3137379589 @default.
• W3136351248 cites W3145860562 @default.
• W3136351248 cites W3172081492 @default.
• W3136351248 doi "https://doi.org/10.1016/j.jtho.2021.10.013" @default.
• W3136351248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34740862" @default.
• W3136351248 hasPublicationYear "2022" @default.
• W3136351248 type Work @default.
• W3136351248 sameAs 3136351248 @default.
• W3136351248 citedByCount "117" @default.
• W3136351248 countsByYear W31363512482022 @default.
• W3136351248 countsByYear W31363512482023 @default.
• W3136351248 crossrefType "journal-article" @default.
• W3136351248 hasAuthorship W3136351248A5001355914 @default.
• W3136351248 hasAuthorship W3136351248A5005948108 @default.
• W3136351248 hasAuthorship W3136351248A5013639614 @default.
• W3136351248 hasAuthorship W3136351248A5013806712 @default.
• W3136351248 hasAuthorship W3136351248A5025095617 @default.
• W3136351248 hasAuthorship W3136351248A5025940494 @default.
• W3136351248 hasAuthorship W3136351248A5028895179 @default.
• W3136351248 hasAuthorship W3136351248A5029805571 @default.
• W3136351248 hasAuthorship W3136351248A5030072277 @default.
• W3136351248 hasAuthorship W3136351248A5030450694 @default.
• W3136351248 hasAuthorship W3136351248A5030622261 @default.
• W3136351248 hasAuthorship W3136351248A5034426537 @default.
• W3136351248 hasAuthorship W3136351248A5035581993 @default.
• W3136351248 hasAuthorship W3136351248A5037884911 @default.
• W3136351248 hasAuthorship W3136351248A5039160380 @default.

• next